Co-Authors
This is a "connection" page, showing publications co-authored by David Neskey and Chrystal Paulos.
Connection Strength
1.162
-
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
Score: 0.205
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.202
-
Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
Score: 0.200
-
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
Score: 0.183
-
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends Cancer. 2019 04; 5(4):208-232.
Score: 0.169
-
Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. Cancer Res. 2022 12 02; 82(23):4386-4399.
Score: 0.055
-
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis. World J Otorhinolaryngol Head Neck Surg. 2022 Sep; 8(3):177-186.
Score: 0.052
-
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.
Score: 0.051
-
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma. BMC Cancer. 2020 Mar 17; 20(1):229.
Score: 0.045